Specialized Bacteriocin Compositions for Niche Environments

Publication ID: 24-11857606_0009_PTD
Published: October 28, 2025
Category:Specialized Variations & Niche Solutions

Legal Citation

pr1or.art Inc., “Specialized Bacteriocin Compositions for Niche Environments,” Published Technical Disclosure No. 24-11857606_0009_PTD, Published October 28, 2025, available at https://archive.pr1or.art/24-11857606_0009_PTD
This technical disclosure describes improvements that would be readily apparent to a Person Having Ordinary Skill In The Art (PHOSITA) when considered in combination with the foundational architecture disclosed in U.S. Patent No. 11,857,606.

Summary of the Inventive Concept

The present inventive concept provides specialized bacteriocin compositions and methods adapted for specific, narrow market or unique operational environments, such as high-security needs, disaster relief, or extreme weather conditions.

Background and Problem Solved

The original patent disclosed therapeutic bacteriocins for reducing growth of microbial colonies. However, the patent did not address the specific challenges of utilizing bacteriocins in extreme or unique environments. The present inventive concept solves this problem by adapting the bacteriocin compositions and methods for these specialized settings.

Detailed Description of the Inventive Concept

The inventive concept comprises bacteriocin compositions with receptor-mediated translocation domains, cargo domains, and labeling domains tailored for specific niches. For example, the composition for high-temperature environments includes a cargo domain that degrades peptidoglycan, while the composition for disaster relief settings features a labeling domain that targets Gram-negative bacteria. The inventive concept also encompasses methods for administering these compositions in these specialized environments.

Novelty and Inventive Step

The new claims introduce novel bacteriocin compositions and methods that are specifically adapted for unique operational environments, which is not addressed in the original patent. The inventive step lies in the recognition of the need for specialized bacteriocin compositions and methods for these niches and the development of tailored solutions.

Alternative Embodiments and Variations

Alternative embodiments of the inventive concept could include bacteriocin compositions with different receptor-mediated translocation domains, cargo domains, or labeling domains for various niche environments. Additionally, the inventive concept could be implemented using different administration methods, such as aerosol delivery or oral administration.

Potential Commercial Applications and Market

The inventive concept has significant commercial potential in industries such as biotechnology, pharmaceuticals, and healthcare, particularly in areas with high-security needs, disaster relief efforts, or extreme weather conditions. The target market includes hospitals, research institutions, and government agencies.

CPC Classifications

SectionClassGroup
A A61 A61K38/43
A A01 A01N63/10
A A01 A01N63/50
C C07 C07K14/21
C C07 C07K14/26
C C12 C12N9/2462

Field of Art

Biotechnology and microbial therapeutics, specifically focused on bacteriocin design and antimicrobial compositions, requiring expertise in protein engineering, microbiology, and molecular biology with advanced degrees and specialized training in bacteriocin mechanisms

Person of Ordinary Skill (PHOSITA) Profile

A researcher or biotechnology professional with a PhD in microbiology or molecular biology, experienced in protein domain manipulation, bacteriocin engineering, and understanding of bacterial targeting mechanisms

Obviousness Rationale

A PHOSITA would recognize that the source patent's bacteriocin structure provides a foundational template for domain-based modifications targeting specific bacterial environments. The PTD's variations represent predictable extensions of known bacteriocin engineering principles, involving standard protein domain recombination and targeted functional modifications. The disclosed niche adaptations would be considered routine optimization within the established bacteriocin design framework.

Obvious Combinations & Variations

Source Patent Element
Receptor-mediated translocation domain from SEQ ID NO:10 segments 1-320
PTD Variation
Adapting the translocation domain for high-temperature or extreme environment performance
Obviousness Reasoning
Modifying protein domains for environmental stability is a known technique in protein engineering, representing a predictable design choice for a PHOSITA
Source Patent Element
Bacteriocin targeting Klebsiella pneumoniae and Escherichia coli
PTD Variation
Adding specialized cargo or labeling domains for specific bacterial targeting in niche environments
Obviousness Reasoning
Expanding bacterial targeting capabilities through domain addition is a standard protein engineering approach with expected, predictable results
Source Patent Element
Base bacteriocin composition with receptor binding and translocation domains
PTD Variation
Introducing administration methods like aerosol delivery for specialized environments
Obviousness Reasoning
Alternative delivery mechanisms represent a straightforward extension of existing bacteriocin therapeutic approaches, obvious to a skilled practitioner
Source Patent Element
Bacteriocin with peptidoglycan-interactive domains
PTD Variation
Developing cargo domains specifically targeting peptidoglycan degradation or synthesis inhibition
Obviousness Reasoning
Refining enzymatic interactions with bacterial cell walls is a predictable optimization within bacteriocin design principles
Source Patent Element
Bacteriocin composition for microbial colony reduction
PTD Variation
Tailoring bacteriocin compositions for specific operational contexts like disaster relief or high-security facilities
Obviousness Reasoning
Contextual adaptation of antimicrobial technologies represents an obvious design choice based on known performance requirements
35 U.S.C. § 103 Summary: Pursuant to 35 U.S.C. ยง 103, the variations disclosed in the instant publication would be considered obvious to a person having ordinary skill in the art at the time of invention, when viewed in light of US Patent 11857606. The claimed bacteriocin modifications represent predictable extensions of known bacteriocin engineering principles, involving routine domain recombination, targeting optimization, and environmental adaptation strategies that would be apparent to a skilled practitioner in the field.

Original Patent Information

Patent NumberUS 11,857,606
TitleTherapeutic bacteriocins
Assignee(s)BACTOCLEAR HOLDINGS PTE. LTD.